Bicycle Therapeutics logo

Bicycle TherapeuticsNASDAQ: BCYC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

23 May 2019

Next earnings report:

20 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.50 B
-20%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
56%vs. sector
-73%vs. 3y high
90%vs. sector

Price

after hours | Fri, 15 Nov 2024 21:02:14 GMT
$21.79-$0.79(-3.50%)

Dividend

No data over the past 3 years
$2.68 M$6.20 M
$2.68 M-$50.80 M

Analysts recommendations

Institutional Ownership

BCYC Latest News

Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern
seekingalpha.com07 November 2024 Sentiment: POSITIVE

Today, we revisit Bicycle Therapeutics plc, a clinical-stage biopharma firm, that has intriguing potential and focuses on developing medicines for unmet needs. The company is advancing several candidates within its pipeline and is well-funded into mid-2027.  The stock also continues to enjoy strong analyst firm support. An updated analysis of Bicycle Therapeutics follows in the paragraphs below.

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?
zacks.com14 October 2024 Sentiment: POSITIVE

Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
businesswire.com14 September 2024 Sentiment: POSITIVE

BARCELONA--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC®) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist.

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
benzinga.com06 September 2024 Sentiment: POSITIVE

RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond.

What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
zacks.com09 August 2024 Sentiment: POSITIVE

Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
zacks.com09 August 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 88.9% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
zacks.com27 June 2024 Sentiment: NEUTRAL

Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
zacks.com11 June 2024 Sentiment: POSITIVE

Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
zacks.com24 May 2024 Sentiment: POSITIVE

Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.

Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet
zacks.com24 May 2024 Sentiment: POSITIVE

The consensus price target hints at an 85.5% upside potential for Bicycle Therapeutics (BCYC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • 1(current)

What type of business is Bicycle Therapeutics?

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

What sector is Bicycle Therapeutics in?

Bicycle Therapeutics is in the Healthcare sector

What industry is Bicycle Therapeutics in?

Bicycle Therapeutics is in the Biotechnology industry

What country is Bicycle Therapeutics from?

Bicycle Therapeutics is headquartered in United Kingdom

When did Bicycle Therapeutics go public?

Bicycle Therapeutics initial public offering (IPO) was on 23 May 2019

What is Bicycle Therapeutics website?

https://www.bicycletherapeutics.com

Is Bicycle Therapeutics in the S&P 500?

No, Bicycle Therapeutics is not included in the S&P 500 index

Is Bicycle Therapeutics in the NASDAQ 100?

No, Bicycle Therapeutics is not included in the NASDAQ 100 index

Is Bicycle Therapeutics in the Dow Jones?

No, Bicycle Therapeutics is not included in the Dow Jones index

When was Bicycle Therapeutics the previous earnings report?

No data

When does Bicycle Therapeutics earnings report?

The next expected earnings date for Bicycle Therapeutics is 20 February 2025